TrialBMC cancer2017

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Thomas Decker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.